Evidence map›Paper›PMID 33950020›Full record

ArticleActa crystallographica. Section D, Structural biology2021

Moving toward generalizable NZ-1 labeling for 3D structure determination with optimized epitope-tag insertion.

Risako Tamura-Sakaguchi, Rie Aruga, Mika Hirose, Toru Ekimoto, Takuya Miyake, Yohei Hizukuri, Rika Oi, Mika K Kaneko, Yukinari Kato, Yoshinori Akiyama and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. A Novel Anti-CD44 Variant 3 Monoclonal Antibody CInternational journal of molecular sciences · 2023
    Article
  4. Article
  5. A Novel Anti-CD44 Variant 9 Monoclonal Antibody CCurrent issues in molecular biology · 2023
    Article
  6. Article
  7. Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody CCurrent issues in molecular biology · 2023
    Article
  8. Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody CInternational journal of molecular sciences · 2023
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Risako Tamura-SakaguchiGraduate School of Medical Life Science, Yokohama City University, Japan.ORCID 0000-0001-7077-6267
Rie ArugaGraduate School of Medical Life Science, Yokohama City University, Japan.
Mika HiroseInstitute for Protein Research, Osaka University, Japan.ORCID 0000-0001-8991-587X
Toru EkimotoGraduate School of Medical Life Science, Yokohama City University, Japan.ORCID 0000-0001-7186-0292
Takuya MiyakeInstitute for Frontier Life and Medical Sciences, Kyoto University, Japan.
Yohei HizukuriInstitute for Frontier Life and Medical Sciences, Kyoto University, Japan.ORCID 0000-0003-0594-1160
Rika OiGraduate School of Medical Life Science, Yokohama City University, Japan.
Mika K KanekoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Japan.
Yukinari KatoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Japan.ORCID 0000-0001-5385-8201
Yoshinori AkiyamaInstitute for Frontier Life and Medical Sciences, Kyoto University, Japan.ORCID 0000-0003-4483-5408
Mitsunori IkeguchiGraduate School of Medical Life Science, Yokohama City University, Japan.ORCID 0000-0003-3199-6931
Kenji IwasakiLife Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance (TARA), University of Tsukuba, Japan.ORCID 0000-0002-3808-8904
Terukazu NogiGraduate School of Medical Life Science, Yokohama City University, Japan.ORCID 0000-0001-8663-3519
Yokohama City University · JPKyoto University · JPTohoku University · JPProtein Research Foundation · JPUniversity of Tsukuba · JP

Funding

Japan Agency for Medical Research and Development 19am0101072j0003Japan Agency for Medical Research and Development JP16am0101020Japan Agency for Medical Research and Development JP20ae0101028Japan Agency for Medical Research and Development JP20am0101009Japan Agency for Medical Research and Development JP20am0101078Japan Agency for Medical Research and Development JP20am0401013Japan Society for the Promotion of Science 19H03170Japan Society for the Promotion of Science JP17K19206Japan Society for the Promotion of Science JP18H02404Japan Society for the Promotion of Science JP19K06562Japan Society for the Promotion of Science JP26291016Ministry of Education, Culture, Sports, Science and Technology 18H05426Ministry of Education, Culture, Sports, Science and Technology hp200129
6 · The paper itself

Abstract

Antibody labeling has been conducted extensively for structure determination using both X-ray crystallography and electron microscopy (EM). However, establishing target-specific antibodies is a prerequisite for applying antibody-assisted structural analysis. To expand the applicability of this strategy, an alternative method has been developed to prepare an antibody complex by inserting an exogenous epitope into the target. It has already been demonstrated that the Fab of the NZ-1 monoclonal antibody can form a stable complex with a target containing a PA12 tag as an inserted epitope. Nevertheless, it was also found that complex formation through the inserted PA12 tag inevitably caused structural changes around the insertion site on the target. Here, an attempt was made to improve the tag-insertion method, and it was consequently discovered that an alternate tag (PA14) could replace various loops on the target without inducing large structural changes. Crystallographic analysis demonstrated that the inserted PA14 tag adopts a loop-like conformation with closed ends in the antigen-binding pocket of the NZ-1 Fab. Due to proximity of the termini in the bound conformation, the more optimal PA14 tag had only a minor impact on the target structure. In fact, the PA14 tag could also be inserted into a sterically hindered loop for labeling. Molecular-dynamics simulations also showed a rigid structure for the target regardless of PA14 insertion and complex formation with the NZ-1 Fab. Using this improved labeling technique, negative-stain EM was performed on a bacterial site-2 protease, which enabled an approximation of the domain arrangement based on the docking mode of the NZ-1 Fab.

Indexed as

Models, MolecularAntibodies, MonoclonalCrystallography, X-RayEpitopesImmunoglobulin Fab FragmentsMicroscopy, ElectronProtein ConformationAntibodies, MonoclonalEpitopesImmunoglobulin Fab Fragmentsantibody-assisted structural analysisantibody labelingelectron microscopyepitope insertionprotein crystallography

Identifiers

PMID33950020
PMCPMC8098476
OpenAlexW3152993484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.